Aurobindo Pharma has incorporated a new wholly owned subsidiary in the name of Engenra Biologics, on February 24, 2026. The object of incorporation of this wholly owned subsidiary is to expand the contract manufacturing and other pharmaceutical manufacturing operations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
